Book Online Consultation

Prof. Muzaffar Latif Gill opinion on Timely Treatment of Hepatitis

Posted on

Prof. Muzaffar Latif Gill shared his opinion on Timely Treatment of Hepatitis with Daily Times on 28th July 2012.


Professor Gill’s Team presented three research papers in 26th conference of ASIA PACIFIC ASSOCIATION & STUDY OF LIVER DISEASE (APASL) which was held from FEB, 15 to 19, 2017 in Shanghai, China

Posted on

Professor Gill’s Team presented three research papers in 26th conference of ASIA PACIFIC ASSOCIATION & STUDY OF LIVER DISEASE (APASL) which was held from FEB, 15 to 19, 2017 in Shanghai, China   These three papers were rated among Top 10% of the […]


Professor Gill’ team has presented research work at international liver conference (ILC) being held in Barcelona , Spain from March 13th to March 17th 2016

Posted on

From: Patricia Pochelon <[email protected]> Date: January 25, 2016 at 8:28:21 PM GMT+5 To: “Prof. Muzzaffar Lateef Gill” Subject: Amendment – ILC 2016 – Abstract notification ABSTRACT NOTIFICATION – EASL – THE INTERNATIONAL LIVER CONGRESS™ 2016 Professor Muzzaffar Gill MAROOF INTERNATIONAL […]


OUTCOMES OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN PATIENTS WITH CIRRHOSIS

Posted on

SIDRA GILL, NOSHEEN YOUSUF, AMMARA NAWAZ, RABBEA NAZIR, MUZZAFFAR GILL Background: ERCP is commonly performed in cirrhotics, they are at increased risk of bleeding after ERCP, but the incidence and risk-factors in this population is not well described. The aim […]


OUTCOMES OF SOF AND RIBA THERAPY FOR HEP C G3 PATIENTS WHO ARE RELAPSERS OF PEG INF AND RIBAVIRIN

Posted on

SIDRA GILL, NOSHEEN YOUSAF, FAIZA IRFAN, AMMARA NAWAZ, UZMA FEYAZ QAZI, MUZZAFFAR GILL MAROOF INTERNATIONAL HOSPITAL, ISLAMABAD, PAKISTAN Background and Aims: Sofosbuvir + Ribavirin is gold standard for chronic HEP-C patients. We evaluated the safety and efficacy of sofosbuvir and […]


OUTCOMES OF SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION

Posted on

SIDRA GILL NOSHEEN YOUSUF, AMMARA NAWAZ , RABBEA NAZIR, MUZZAFFAR GILL Background: Recurrent hepatitis occurs in the vast majority of HCV-positive recipients who are viremic at the time of Liver Transplantation (LT). We evaluated safety and efficacy of all oral […]


Certificate of APASL, Awarded to Prof. Muzzaffar Gill for Moderating Conference.

Posted on

Certificate of APASL, Awarded to Prof. Muzzaffar Gill for Moderating Conference.


OUTCOMES OF SOF, RIBA AND PEG-INF THERAPY FOR THE TREATMENT OF CHRONIC HEP-C G3 TREATMENT NAIVE PATIENTS

Posted on

SIDRA GILL, NOSHEEN YOUSAF, FAIZA IRFAN, AMMARA NAWAZ, UZMA FEYAZ QAZI, MUZZAFFAR GILL MAROOF INTERNATIONAL HOSPITAL, ISLAMABAD, PAKISTAN Background: Sovaldi, Ribavirin and PEG-Interferon is gold standard therapy for chronic HEP-C patients. It is recommended both for treatment naive and experienced […]


Professor Gill’s team presented four research papers in Tokyo Japan.

Posted on

Professor Gill’s team has presented four research research papers In 25th Asian Pacific association for study of liver diseases (APASL) Which was held in Tokyo Japan from Feb 20-24 , 2016 On behalf of the 25th Asian Pacific Association for […]